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The assessment of outcome in schizophrenia has changed
significantly in the last decade. The introduction of the
novel antipsychotic drugs and the movement of commu-
nity psychiatry and deinstitutionalization has shifted
attention to functioning of the patient in everyday situa-
tions, satisfaction from life, the fulfillment of social roles
and interpersonal communication. These domains consti-
tute the so-called "Quality of Life" (QoL). QoL is a com-
plex phenomenon, dependent on many factors that
interrelate to each other. In schizophrenia in particular,
research has underlined the importance of the following
factors related to the QoL of the patients.
Experiences related to the medication. These refer to the
effectiveness of the medication to alleviate positive as well
as negative symptoms, side effects (e.g. extrapyramidal
symptoms, sedation, effect on the sexual function) and
their consequences in everyday life.
Insight of the patient into his condition and the restric-
tions imposed by the illness.
Compliance to medication, related to the above men-
tioned two factors. This refers to experiences with previous
medications, the characteristics of current medication,
dosage and the route of administration of the medication,
as well as to idiosyncratic factors and factors related to the
stage of the illness and symptomatology (responiveness to
antipsychotic drugs, insight). Compliance is also related
to the type of care offered to the patient (continuity of care
vs. fragmented care), in the sense that continuous care
ensures that the patient is not lost during his "career",
being followed up at regular times and having access to
the services at all times.
There is very little research into the effect of compliance in
the QoL in schizophrenia. The complexity of the phenom-
enon makes its study difficult, since the interrelations
between factors are not yet clear as well the direction of
effect. However, the existing research shows that
improved compliance ensures a better QoL for schizo-
phrenic patients. The introduction of the novel antipsy-
chotics and newer formulations, with less side effects, is
promising not only for their effectiveness in minimizing
symptoms of the illness, but also for improving compli-
ance and QoL.
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